1. In Vitro ELISA and Cell-Based Assays Confirm the Low Immunogenicity of VNAR Therapeutic Constructs in a Mouse Model of Human RA: An Encouraging Milestone to Further Clinical Drug Development. (3rd February 2020) Authors: Ubah, Obinna C.; Porter, Andrew J.; Barelle, Caroline J. Other Names: Stijlemans Benoit Academic Editor. Journal: Journal of immunology research Issue: Volume 2020(2020) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Next-generation flexible formats of VNAR domains expand the drug platform's utility and developability. (17th December 2018) Authors: Ubah, Obinna C.; Buschhaus, Magdalena J.; Ferguson, Laura; Kovaleva, Marina; Steven, John; Porter, Andrew J.; Barelle, Caroline J. Journal: Biochemical Society transactions Issue: Volume 46:Number 6(2018) Page Start: 1559 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Next-generation flexible formats of VNAR domains expand the drug platform's utility and developability. (31st October 2018) Authors: Ubah, Obinna C.; Buschhaus, Magdalena J.; Ferguson, Laura; Kovaleva, Marina; Steven, John; Porter, Andrew J.; Barelle, Caroline J. Journal: Biochemical Society transactions Issue: Volume 46:Number 6(2018) Page Start: 1559 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗